Switching to pressurized metered-dose inhaler improves asthma control, says study

Published On 2019-09-02 13:50 GMT   |   Update On 2019-09-02 13:50 GMT

Delhi: Switching from a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) decreased exacerbations and improved disease control in asthma patients, reveals a recent study published in the journal Respirology. This was observed in the patients treated with fixed-dose combination inhaled corticosteroid/long-acting β2-agonist (FDC ICS/LABA).


The use of a mixed inhaler for asthma treatment results in worse inhaler technique and outcomes. Changing preventers from dry powder inhalers to pMDI may improve asthma outcome provide that relievers are commonly prescribed as pressurized metred‐dose inhalers.



David B. Price, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK, and colleagues aimed to assess the persistence and effectiveness of switching from DPI to pMDI for inhaled corticosteroid and long‐acting β2‐agonist combination therapy (ICS/LABA).


The persistence of the switch was defined as receiving ≥1 pMDI and no DPI following the switch. Effectiveness of the switch was assessed as the proportion of patients without severe asthma exacerbation and the proportion who achieved risk domain asthma control (RDAC), defined as no asthma-related hospitalization, antibiotics without upper respiratory diagnosis, or acute course of oral corticosteroids, and overall asthma control, (OAC), defined as RDAC and ≤200 µg salbutamol/≤500 µg terbutaline average daily dose, which were compared 1 year following and 1 year prior to the switch.

The study included 2 cohorts: a total switch cohort and an effectiveness cohort. The total switch cohort sought to assess the persistence of a switch from the previous DPI to a pMDI prescription. This cohort included a 1-year baseline period and a 6-month outcome period. The purpose of the effectiveness cohort was to assess the effectiveness of switching from a DPI to a pMDI. This cohort included a 1-year baseline period for patient characterization prior to the index date (ie, the date of first pMDI prescription) and a 1-year outcome period for endpoint measures.


Also Read: FDA approves Digital inhaler for Asthma patients aged 12 years and above

Key findings of the study include:

  • Within 85 patients who switched from DPI to pMDI and persisted for a year, a higher proportion were free from asthma exacerbation after the switch.

  • Switching to pMDI was also associated with better RDAC (75.3% vs 57.7%) and OAC (57.7% vs 45.9%).

  • From the entire 117 patients who switched to fixed‐dose combination (FDC)/ICS LABA pMDI, 76.1% of patients persisted in the following 6 months.


Also Read: Corticosteroid inhalers in COPD patients offer protection against lung cancer, finds new study

"The findings from this study demonstrated that in a real-life specialist asthma setting, switching from an FDC ICS/LABA to a pMDI was associated with a significantly lower proportion of patients who experienced severe asthma exacerbations and was linked to better asthma control compared with the prior year when the patients were on DPI prescriptions," concluded the authors. "The majority of patients maintained the switch for ≥6 months."


To read the complete study log on to https://doi.org/10.1111/resp.13559
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News